Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
$8.10
-3.1%
$7.05
$5.47
$11.99
$167.97MN/A67,305 shs32,359 shs
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
$3.30
-31.4%
$2.80
$0.66
$17.75
$19.93M0.3822.03 million shs72.02 million shs
Cybin Inc. stock logo
CYBN
Cybin
$7.30
+2.0%
$7.68
$4.81
$13.88
$171.50M0.68322,049 shs609,079 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$13.01
-0.5%
$13.02
$7.09
$27.38
$163.77M0.45194,157 shs72,780 shs
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
0.00%+2.96%+15.15%-19.07%+3.47%
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
0.00%-53.13%+10.00%+250.28%+60.98%
Cybin Inc. stock logo
CYBN
Cybin
0.00%+1.27%-10.51%-4.28%+1,837.67%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%-3.04%-4.60%+3.32%+52.09%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
0.506 of 5 stars
0.02.00.00.02.91.70.0
Cybin Inc. stock logo
CYBN
Cybin
2.4108 of 5 stars
3.60.00.00.01.70.81.3
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.6984 of 5 stars
3.50.01.72.70.02.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
3.00
Buy$20.50153.09% Upside
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
0.00
N/AN/AN/A
Cybin Inc. stock logo
CYBN
Cybin
3.25
Buy$85.001,065.18% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50134.44% Upside

Current Analyst Ratings Breakdown

Latest ATNF, LFVN, CYBN, and ACTU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
8/14/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
7/29/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
7/12/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
7/8/2025
Cybin Inc. stock logo
CYBN
Cybin
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$73.00 ➝ $70.00
6/27/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
6/11/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
6/3/2025
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$20.00
(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/A$0.01 per shareN/A
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/AN/AN/AN/A$2.91 per shareN/A
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/A$10.83 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$222.35M0.74$0.88 per share14.83$2.05 per share6.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
-$27.28MN/A0.00N/AN/AN/A-281.83%N/A
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
-$6.17M-$15.07N/AN/AN/A-141.25%-80.77%11/12/2025 (Estimated)
Cybin Inc. stock logo
CYBN
Cybin
-$57.88M-$4.60N/AN/AN/AN/A-37.58%-36.59%N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.86N/A4.12%34.67%15.24%8/27/2025 (Estimated)

Latest ATNF, LFVN, CYBN, and ACTU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/4/2025Q4 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.17N/AN/AN/A$57.93 millionN/A
8/14/2025Q2 2025
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
-$0.19-$0.30-$0.11-$0.30N/AN/A
7/23/2025Q2 2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/A-$0.30N/A-$0.30N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/AN/AN/AN/AN/A
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.38%N/A26.09%3 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/A
0.73
0.46
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/A
0.58
0.58
Cybin Inc. stock logo
CYBN
Cybin
N/A
24.24
24.24
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98

Institutional Ownership

CompanyInstitutional Ownership
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/A
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
4.07%
Cybin Inc. stock logo
CYBN
Cybin
17.94%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%

Insider Ownership

CompanyInsider Ownership
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
69.34%
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
38.20%
Cybin Inc. stock logo
CYBN
Cybin
15.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
1020.75 million6.36 millionN/A
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
76.04 million3.73 millionNo Data
Cybin Inc. stock logo
CYBN
Cybin
5023.59 million17.96 millionNot Optionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable

Recent News About These Companies

LifeVantage To Open Iceland Market

New MarketBeat Followers Over Time

Media Sentiment Over Time

Actuate Therapeutics stock logo

Actuate Therapeutics NASDAQ:ACTU

$8.10 -0.26 (-3.11%)
As of 03:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

180 Life Sciences stock logo

180 Life Sciences NASDAQ:ATNF

$3.30 -1.51 (-31.39%)
As of 08/22/2025

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Cybin stock logo

Cybin NYSE:CYBN

$7.30 +0.15 (+2.03%)
As of 03:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$13.01 -0.07 (-0.54%)
As of 03:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.